Research Article

Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma

Published: September 09, 2016
Genet. Mol. Res. 15(3): gmr8582 DOI: https://doi.org/10.4238/gmr.15038582
Cite this Article:
L.H. Zhang, B.B. Hao, C.Y. Zhang, X.Z. Dai, F. Zhang, L.H. Zhang, B.B. Hao, C.Y. Zhang, X.Z. Dai, F. Zhang (2016). Contributions of polymorphisms in miR146a, miR196a, and miR499 to the development of hepatocellular carcinoma. Genet. Mol. Res. 15(3): gmr8582. https://doi.org/10.4238/gmr.15038582
2,098 views

Abstract

Hepatocellular carcinoma is one of the most common malignant tumors worldwide; it is estimated that there were 782,000 new cases in 2012. MicroRNAs (miRNAs) play an important role in carcinogenesis by regulating oncogenes and tumor suppressors. We investigated the role of miR-146a, miR-196a2, and miR-499 polymorphisms in the risk of hepatocellular carcinoma in a Chinese population. Hepatocellular carcinoma patients (175) and healthy controls (302) were recruited between April 2013 and March 2015. Genotype analysis of miR-146a, miR-196a2, and miR-499 polymorphisms was carried out by polymerase chain reaction-restriction fragment length polymorphism. There was a significant difference between the genotype distribution of miR-196a2 in hepatocellular carcinoma patients and controls (X2 = 17.23, P

Hepatocellular carcinoma is one of the most common malignant tumors worldwide; it is estimated that there were 782,000 new cases in 2012. MicroRNAs (miRNAs) play an important role in carcinogenesis by regulating oncogenes and tumor suppressors. We investigated the role of miR-146a, miR-196a2, and miR-499 polymorphisms in the risk of hepatocellular carcinoma in a Chinese population. Hepatocellular carcinoma patients (175) and healthy controls (302) were recruited between April 2013 and March 2015. Genotype analysis of miR-146a, miR-196a2, and miR-499 polymorphisms was carried out by polymerase chain reaction-restriction fragment length polymorphism. There was a significant difference between the genotype distribution of miR-196a2 in hepatocellular carcinoma patients and controls (X2 = 17.23, P